March 6: The Week in Cancer News
Some people with prostate cancer may not need hormone therapy, and colorectal cancer cases shift increasingly to younger adults.
Progress Against Cancer
Some people with prostate cancer may not need hormone therapy, and colorectal cancer cases shift increasingly to younger adults.
The FDA has approved teclistamab with daratumumab hyaluronidase-fihj for certain patients with pretreated multiple myeloma. The U.S. Food and Drug Administration (FDA) approved teclistamab (Tecvayli) in combination with daratumumab hyaluronidase-fihj (Darzalex Faspro) for adult...
Epidemiologist Elizabeth A. Platz explains what goes into calculating cancer risk estimates, such as rate ratio, hazard ratio, and absolute risk.
Zongertinib was granted accelerated approval as a first-line treatment for adults with advanced non-squamous non-small cell lung cancer with HER2-activating mutations. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to zongertinib...
The FDA has converted the accelerated approval of encorafenib and cetuximab plus chemotherapy to full approval for first-line treatment of certain colorectal cancers. The U.S. Food and Drug Administration (FDA) has granted traditional approval...
First tumor treating fields device for pancreatic cancer approved, and hair extension products often contain potentially dangerous chemicals.
Elizabeth M. Jaffee and Philip D. Greenberg opened AACR IO 2026 with a look at cancer vaccines and the next generation of engineered T cells.
The second-generation BTK inhibitor acalabrutinib was approved for use with venetoclax. The U.S. Food and Drug Administration (FDA) approved acalabrutinib (Calquence) in combination with venetoclax (Venclexta) for adults with chronic lymphocytic leukemia (CLL) or...
Colorectal cancer cases are becoming more common in younger adults, but there are now more options for screening beyond colonoscopies.
Misinformation reaches most breast cancer survivors, and the FDA approves a treatment combination for platinum-resistant epithelial ovarian cancer.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More